These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38587730)

  • 21. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder.
    Dowd WN; Barch DH; Seibert JH; Mark TL
    J Subst Abuse Treat; 2022 Sep; 140():108824. PubMed ID: 35780730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
    Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
    JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
    Speight C; Caiola C; Tyndall DE; Scott ES
    J Am Assoc Nurse Pract; 2023 Feb; 35(2):112-121. PubMed ID: 36512806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina.
    Oros SM; Christon LM; Barth KS; Berini CR; Padgett BL; Diaz VA
    Int J Psychiatry Med; 2021 Jan; 56(1):14-39. PubMed ID: 32726568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics.
    Ober AJ; Dopp AR; Clingan SE; Curtis ME; Lin C; Calhoun S; Larkins S; Black M; Hanano M; Osterhage KP; Baldwin LM; Saxon AJ; Hichborn EG; Marsch LA; Mooney LJ; Hser YI
    J Subst Use Addict Treat; 2024 Jan; 156():209194. PubMed ID: 37863356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deploying science to change hearts and minds: Responding to the opioid crisis.
    Walsh SL; Long KQX
    Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
    Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
    Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
    Madden EF; Prevedel S; Light T; Sulzer SH
    Subst Use Misuse; 2021; 56(14):2181-2201. PubMed ID: 34538213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
    Bogan C; Jennings L; Haynes L; Barth K; Moreland A; Oros M; Goldsby S; Lane S; Funcell C; Brady K
    J Subst Abuse Treat; 2020 Mar; 112S():73-78. PubMed ID: 32220414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Barriers and facilitators to implementing medications for opioid use disorder and naloxone distribution in Veterans Affairs emergency departments.
    Sasson C; Dieujuste N; Klocko R; Basrai Z; Celedon M; Hsiao J; Himstreet J; Hoffman J; Pfaff C; Malmstrom R; Smith J; Holstein A; Johnson-Koenke R
    Acad Emerg Med; 2023 Apr; 30(4):289-298. PubMed ID: 36757683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health professionals' attitudes toward medications for opioid use disorder.
    Brown AR
    Subst Abus; 2022; 43(1):598-614. PubMed ID: 34520703
    [No Abstract]   [Full Text] [Related]  

  • 36. Initiation of Buprenorphine in the Emergency Department: A Survey of Emergency Clinicians.
    Barkley A; Lander L; Dilcher B; Tuscano M
    West J Emerg Med; 2024 Jul; 25(4):470-476. PubMed ID: 39028232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variation in Use of Medications for Opioid Use Disorder in Critically Ill Patients Across the United States.
    Feeney ME; Law AC; Walkey AJ; Bosch NA
    Crit Care Med; 2024 Jul; 52(7):e365-e375. PubMed ID: 38501933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
    Cioe K; Biondi BE; Easly R; Simard A; Zheng X; Springer SA
    J Subst Abuse Treat; 2020 Dec; 119():108146. PubMed ID: 33138929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
    Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
    J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates.
    Paul N; Kennedy AJ; Taubenberger S; Chang JC; Hacker K
    Subst Abus; 2022; 43(1):742-748. PubMed ID: 35100094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.